A Case of Parathyroid Carcinoma Visualized on Tc-99m-Sestamibi Scintigraphy

Reingard M. Aigner; G. F. Fueger; S. Lax

doi:10.1055/s-0038-1629843

Nuklearmedizin - NuclearMedicine, Table of Contents

Nuklearmedizin 1997; 36(07): 256-258
DOI: 10.1055/s-0038-1629843

Originalarbeiten — Original Articles

Schattauer GmbH

A Case of Parathyroid Carcinoma Visualized on Tc-99m-Sestamibi Scintigraphy

Ein Fall von Nebenschilddrüsenkarzinom dargestellt mittels Tc-99m-Sestamibi

Reingard M. Aigner

¹From the Department of Radiology, Division of Nuclear Medicine, Austria

,

G. F. Fueger

¹From the Department of Radiology, Division of Nuclear Medicine, Austria

,

S. Lax

²Institute of Pathology, Karl-Franzens-University of Graz, Austria

› Author Affiliations

Abstract

Summary

Recent studies indicate that Tc-99m-Sestamibi (MIBI, DuPont Pharma) is a useful tracer for detecting parathyroid adenomas. We present a patient with focal Tc-99m-MIBI uptake in parathyroid carcinoma which has only been described once before (1). Tc-99m-MIBI scintigraphy may be considered for diagnosing pathological parathyroid tissue. But presently the histopathological examination only allows the differentiation between adenoma and carcinoma.

Zusammenfassung

In der rezenten wissenschaftlichen Literatur wird Tc-99m-Sestamibi (MIBI, DuPont Pharma) als gut geeigneter Tracer zum Nachweis von Nebenschilddrüsenadenomen dargestellt. Wir berichten über einen Patienten bei dem lokalisiert gesteigerter Uptake von Tc-99m-Sestamibi in einem Nebenschilddrüsenkarzinom nachgewiesen wurde. Dies wurde in der Literatur erst einmal beschrieben (1). Tc-99m-Sestamibi kann zur Diagnose von pathologischem Nebenschilddrüsengewebe verwendet werden. Gegenwärtig erlaubt nur die histopathologische Untersuchung die Differenzierung zwischen Adenom und Karzinom

Key words

Tc-99m-Sestamibi - parathyroid carcinoma - parathyroid adenoma

Schlüsselwörter

Tc-99m-Sestamibi - Nebenschilddrüsenkarzinom - Nebenschilddrüsen-adenom

Full Text

References

References
1 De Lellis RA. Tumours of the Parathyroid Gland. Atlas of Tumour Pathology, 3rd series, Fascicle 6. AFIP 1993; 16.
2 Schantz A, Castleman B. Parathyroid carcinoma: a study of 70 cases. Cancer 1973; 31: 600.
3 DeLellis RA. Tumours of the Parathyroid Gland. Atlas of Tumour Pathology 3rd series, Fascicle 6. AFIP 1993; 53-63.
4 Coakley AJ, Kettle AG, Wells CP, O’Doherty MJ, Collins REC. 99m-Tc-Sestamibi- a new agent for parathyroid imaging. Nucl Med Com 1989; 10: 791-4.
5 Casara D, Rubello D, Saladini G. et al. Clinical role of Tc-99m-MIBI scintigraphy in parathyroid imaging, a comparative study with Tl-201 scintigraphy, echography and CT. Eur J Nucl Med 1991; 18: 531.
6 Geatti O, Shapiro B, Orsolon PG, Proto G, Guerra UG, Antonucci F, Gasparini D. Localization of parathyroid enlargement: experience with technetium-99m methoxyi-sobutylisonitrile and thallium-201 scintigraphy, ultrasonography and computed tomography. Eur J Nucl Med 1994; 21: 17-22.
7 Osmanagaoglu K, Schelstraete K, Lippens M, Obrie E, De Feyter I. Visualization of a Parathyroid Adenoma with Tc-99m-MIBI in a Case with Iodine Saturation and Impaired Thallium Uptake. Clin Nucl Med 1993; 18: 214-6.
8 Piwicna-Worms D, Kronauge JF, Holman BL, Lister-James J, Davison A, Jones AG. Hexa-kis(carbomethoxyisopropyl-isonitrile)techne-tium(I), a new myocardial perfusion imaging agent: binding characteristics in cultured chick heart cells. J Nucl Med 1988; 29: 55-61.
9 Piwicna-Worms D, Holman BL. Noncardiac applications of hexakis-(alkylisonitrile)tech-netium-99m-complexes. J Nucl Med 1990; 7: 1166-7.